Payment overview · 2025
General Payments
$2,897.95
140 reported records · 32 companies
Healthcare provider profile · identity verified
Marc L Cohen, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ANDERSON, IN · NPI 1942461165
Verified facts
What the public records show
CMS Open Payments records show Marc L Cohen, MD received $2,897.95 in general payments during 2025 across 140 reported records.
ABBVIE INC. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Epidiolex, Ingrezza, Nuplazid, Nurtec Odt, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nuplazid by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Epidiolex by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $752.51 | 26.0% | 52 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $215.28 | 7.4% | 9 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $185.14 | 6.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $184.46 | 6.4% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$166.78 | 5.8% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $107.42 | 3.7% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$93.69 | 3.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.55 | 3.0% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $84.98 | 2.9% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $81.22 | 2.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.61 | 2.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.80 | 2.6% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $68.07 | 2.4% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $67.40 | 2.3% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.64 | 2.2% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.01 | 2.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.28 | 2.1% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $58.00 | 2.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $47.85 | 1.6% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.53 | 1.6% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $35.82 | 1.2% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.68 | 1.2% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.57 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.47 | 1.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.22 | 1.1% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.84 | 0.8% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.25 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.50 | 0.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $21.71 | 0.8% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.74 | 0.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.99 | 0.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.94 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,897.95 | 140 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $327.48 | 28 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $250.85 | 11 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $250.80 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $217.41 | 22 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $185.14 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $184.46 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $166.78 | 4 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $107.42 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.55 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $68.07 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $62.64 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $62.01 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $61.28 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $58.28 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $58.00 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $57.84 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $51.38 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $47.78 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $45.53 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $33.60 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $33.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.45 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $30.27 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 562 | 170 |
| Memantine Hcl | Memantine Hcl | 499 | 142 |
| Gabapentin | Gabapentin | 298 | 103 |
| Topiramate | Topiramate | 242 | 64 |
| Levetiracetam | Levetiracetam | 219 | 52 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 184 | 61 |
| Sumatriptan Succinate | Sumatriptan Succinate | 115 | 28 |
| Primidone | Primidone | 105 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 35 |
| Divalproex Sodium Er | Divalproex Sodium | 85 | 14 |
| Pregabalin | Pregabalin | 83 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 21 |
| Aimovig Autoinjector | Erenumab-Aooe | 67 | 12 |
| Buspirone Hcl | Buspirone Hcl | 62 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 62 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 53 | 22 |
| Meclizine Hcl | Meclizine Hcl | 52 | 33 |
| Rizatriptan | Rizatriptan Benzoate | 52 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 23 |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Baclofen | Baclofen | 43 | 15 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Clonazepam | Clonazepam | 39 | 12 |
| Lacosamide | Lacosamide | 34 | suppressed |
| Entacapone | Entacapone | 33 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | 13 |
| Diazepam | Diazepam | 32 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 29 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 15 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Dalfampridine Er | Dalfampridine | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Kesimpta Pen | Ofatumumab | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Felbamate | Felbamate | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,897.95 · 140 records | ABBVIE INC. | AUSTEDO XR, Apokyn, BOTOX, BRIUMVI, Briviact, CREXONT, EPIDIOLEX, Evrysdi, FYCOMPA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LUMRYZ, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, PONVORY, QULIPTA, REXULTI, Rystiggo, Senza, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, WAKIX, XYWAV, Xeomin, ZAVZPRET, ZEPBOUND, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Epidiolex play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error